Twenty-four patients with severe sepsis in the medical intensive care unit were randomized 1:1:1 to receive intravenous infusions every six hours for four days of ascorbic acid: Lo-AscA (50 mg/kg/24 h, n = 8), or Hi-AscA (200 mg/kg/24 h, n = 8), or Placebo (5% dextrose/water, n = 8).
#MONIT GTN 2.6 USED FOR TRIAL#
The objective of this randomized, double-blind, placebo-controlled, phase I trial was to determine the safety of intravenously infused ascorbic acid in patients with severe sepsis. Parenterally administered ascorbic acid modulates sepsis-induced inflammation and coagulation in experimental animal models. Journal of translational medicine, 12, 32. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. A., Knowlson, S., Sculthorpe, R., Farthing, D., DeWilde, C. Phase I Safety Trial of Intravenous Ascorbic Acid in Patients with Severe Sepsisįowler, A. IVAA may partially correct FID and consequently help rHuEpo hyporesponsive anemia. Vitamin C was not given the first three months in group II (control group, first three months of the study), who then received 500 mg IV three times a week for the next three months. In group I IV vitamin C 500 mg was administered three times a week for three months and discontinued in the next three months of the study. Twenty-seven HD patients with serum ferritin >300 microg/l, transferrin saturation (TS) <20% and hemoglobin (Hb) <10 g/dL were selected andrandomly divided into two groups to enter a cross-over trial with IVAA. The aim of our study was to show the effects of IVAA on FID and whether this results in a better correction of anemia in HD patients with stable hemoglobin (Hb) concentration and FID. Recent studies suggest that intravenous ascorbic acid (IVAA) may circumvent rHuEpo resistance. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial. Giancaspro, V., Nuzziello, M., Pallotta, G., Sacchetti, A., & Petrarulo, F. Intravenous Ascorbic Acid in Hemodialysis Patients with Functional Iron Deficiency: A Clinical Trial
Long-term safety studies of IV iron co-administered with Vitamin C are warranted. Both IS and IS + C induced serum cytokine activation accompanied by lipid peroxidation, however, IS + C induced higher plasma concentrations of F2-isoprostanes, IL-1, IL-10, and TNF-α post-infusion. Thirteen patients with end-stage renal disease on hemodialysis and four healthy controls were assigned to receive 100 mg of IV iron sucrose (IS) or 100 mg of IV IS co-administered with 300 mg of IV Vitamin C (IS + C) in random sequence. This was a prospective, open-label, crossover study.
However, Vitamin C can act as a pro-oxidant in the presence of iron. Vitamin C has emerged as a potential therapy to improve anemia treatment by enhancing iron mobilization. Reticuloendothelial blockade in hemodialysis patients prevents optimal intravenous (IV) iron utilization. Effect of intravenous vitamin C on cytokine activation and oxidative stress in end-stage renal disease patients receiving intravenous iron sucrose. Effect of Intravenous Vitamin C on Cytokine Activation and Oxidative Stress in End-Stage Renal Disease Patients Receiving Intravenous Iron SucroseĬonner, T.